Company · CIK 1652130
Intellia Therapeutics, Inc.
| CIK | 1652130 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2835 — In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
| Business address | MA |
| Listed | NTLA (Nasdaq) |
| First annual or quarterly report | 2016-06-03 |
Offerings
6 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-275740 | 2023-11-24 | 2026-04-29 | 6 | |
| 333-251022 | 2020-11-30 | 2022-12-01 | 7 | |
| 333-227814 | 2018-10-12 | 2020-06-03 | 4 | |
| 333-233448 | 2019-08-23 | 2019-09-12 | 2 | |
| 333-218508 | 2017-06-05 | 2017-11-03 | 4 | |
| 333-210689 | 2016-04-11 | 2016-05-06 | 7 |
Filings
31| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2026-04-29 | 424B5Shelf takedown | 333-275740 | 0001193125-26-192361 |
| 2026-04-27 | 424B5Shelf takedown | 333-275740 | 0001193125-26-182419 |
| 2026-03-02 | 424B5Shelf takedown | 333-275740 | 0001193125-26-085425 |
| 2024-02-26 | 424B5Shelf takedown | 333-275740 | 0001193125-24-045305 |
| 2024-02-23 | 424B5Shelf takedown | 333-275740 | 0001193125-24-044711 |
| 2023-11-24 | S-3ASRShelf registered | 333-275740 | 0001193125-23-282618 |
| 2022-12-01 | 424B5Shelf takedown | 333-251022 | 0001193125-22-296651 |
| 2022-03-04 | 424B5Shelf takedown | 333-251022 | 0001193125-22-066277 |
| 2021-07-01 | 424B5Shelf takedown | 333-251022 | 0001193125-21-206461 |
| 2021-06-28 | 424B5Shelf takedown | 333-251022 | 0001193125-21-201898 |
| 2020-12-02 | 424B5Shelf takedown | 333-251022 | 0001193125-20-308366 |
| 2020-11-30 | 424B5Shelf takedown | 333-251022 | 0001193125-20-305713 |
| 2020-11-30 | S-3ASRShelf registered | 333-251022 | 0001193125-20-305560 |
| 2020-06-03 | 424B5Shelf takedown | 333-227814 | 0001193125-20-159684 |
| 2020-06-01 | 424B5Shelf takedown | 333-227814 | 0001193125-20-157348 |
| 2019-09-12 | EFFECTDeclared effective | 333-233448 | 9999999995-19-002079 |
| 2019-08-23 | S-3Shelf registered | 333-233448 | 0001193125-19-228025 |
| 2019-06-06 | EFFECTDeclared effective | 333-227814 | 9999999995-19-001290 |
| 2018-10-12 | S-3ASRShelf registered | 333-227814 | 0001193125-18-298490 |
| 2017-11-03 | 424B5Shelf takedown | 333-218508 | 0001193125-17-331400 |
| 2017-11-01 | 424B5Shelf takedown | 333-218508 | 0001193125-17-328193 |
| 2017-06-16 | EFFECTDeclared effective | 333-218508 | 9999999995-17-001572 |
| 2017-06-05 | S-3Shelf registered | 333-218508 | 0001193125-17-194753 |
| 2016-05-06 | 424B4Final prospectus | 333-210689 | 0001193125-16-582013 |
| 2016-05-05 | EFFECTDeclared effective | 333-210689 | 9999999995-16-004552 |
| 2016-05-05 | S-1/AAmendment | 333-210689 | 0001193125-16-578675 |
| 2016-04-27 | S-1/AAmendment | 333-210689 | 0001193125-16-558271 |
| 2016-04-19 | S-1/AAmendment | 333-210689 | 0001193125-16-545752 |
| 2016-04-12 | S-1/AAmendment | 333-210689 | 0001193125-16-538753 |
| 2016-04-11 | S-1Registration filed | 333-210689 | 0001193125-16-537163 |
| 2015-09-04 | DRSDraft made public | 377-01139 | 0001564590-15-007753 |